Tirzepatide Plus Basal Insulin Achieves Significant HbA1c Reductions in Uncontrolled T2DM Read more about Tirzepatide Plus Basal Insulin Achieves Significant HbA1c Reductions in Uncontrolled T2DM
Do Severe Mental Illnesses Alter Early Diabetes Treatment Decisions? Read more about Do Severe Mental Illnesses Alter Early Diabetes Treatment Decisions?
How far do GLP-1 benefits reach? New data point toward reduced neurodegeneration Tags Dopamine-D2 receptor agonist Read more about How far do GLP-1 benefits reach? New data point toward reduced neurodegeneration
Could GLP-1 therapy change long-term survival after TAVI in type 2 diabetes? Read more about Could GLP-1 therapy change long-term survival after TAVI in type 2 diabetes?
Empagliflozin Outperforms Metformin in Improving Glucose Stability and Metabolic Health Read more about Empagliflozin Outperforms Metformin in Improving Glucose Stability and Metabolic Health
Real-World Data Align With SEPRA Trial Findings for Weekly Semaglutide Read more about Real-World Data Align With SEPRA Trial Findings for Weekly Semaglutide
Glucagon Remains Underprescribed Among High-Risk Patients With Diabetes Read more about Glucagon Remains Underprescribed Among High-Risk Patients With Diabetes
Once-Weekly Dulaglutide Plus Basal Insulin Improves Glycemic Stability After Kidney Transplantation Read more about Once-Weekly Dulaglutide Plus Basal Insulin Improves Glycemic Stability After Kidney Transplantation
SGLT2 Inhibitors Show Greater Treatment Persistence Than GLP-1 RAs in T2DM Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Show Greater Treatment Persistence Than GLP-1 RAs in T2DM
Incretin Therapies Show Modest Biliary Disease Risk Without Pancreatitis Concern Tags Dopamine-D2 receptor agonist SGLT-2 Inhibitor Read more about Incretin Therapies Show Modest Biliary Disease Risk Without Pancreatitis Concern